Biotech | March 14, 2022
Clarivate deals report highlights emerging trends in biopharma deal-making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
The antimicrobial resistance alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The company will market it under the brand name Molflu
Subscribe To Our Newsletter & Stay Updated
